应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01177 中国生物制药
休市中 10-09 16:08:08
5.410
-0.075
-1.37%
最高
5.550
最低
5.355
成交量
7,267万
今开
5.550
昨收
5.485
日振幅
3.56%
总市值
1,011亿
流通市值
1,011亿
总股本
186.83亿
成交额
3.93亿
换手率
0.39%
流通股本
186.83亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
【券商聚焦】中泰国际：多家药企将公布重要数据 推荐创新药与CXO龙头
金吾财讯 · 10-09 08:38
【券商聚焦】中泰国际：多家药企将公布重要数据 推荐创新药与CXO龙头
新股消息 | 传圣因生物拟于明年赴港上市 已保密递交申请
智通财经 · 10-08 18:50
新股消息 | 传圣因生物拟于明年赴港上市 已保密递交申请
中国生物制药：附属公司TQC3721吸入混悬液III期临床完成全部受试者入组
财中社 · 10-08 17:47
中国生物制药：附属公司TQC3721吸入混悬液III期临床完成全部受试者入组
中国生物制药(01177.HK)：TQC3721吸入混悬液“PDE3/4抑制剂”III期注册临床完成全部受试者入组
智通财经 · 10-08 17:33
中国生物制药(01177.HK)：TQC3721吸入混悬液“PDE3/4抑制剂”III期注册临床完成全部受试者入组
异动解读｜中国生物制药盘中下跌3.08%，跟随行业调整
行情直击 · 10-08 15:06
异动解读｜中国生物制药盘中下跌3.08%，跟随行业调整
港股开盘受压 恒指低开0.41% 汇丰控股（00005）跌2.40%
金吾财讯 · 10-08 09:27
港股开盘受压 恒指低开0.41% 汇丰控股（00005）跌2.40%
【特约大V】邓声兴：外围暖恒指望企稳，科技超卖或先弹
金吾财讯 · 10-07
【特约大V】邓声兴：外围暖恒指望企稳，科技超卖或先弹
港股异动 | 创新药概念股涨势延续 美银指近期三项重磅合作强化板块动能 ESMO有望带来密集催化
智通财经 · 10-06
港股异动 | 创新药概念股涨势延续 美银指近期三项重磅合作强化板块动能 ESMO有望带来密集催化
创新药概念普升 歌礼制药-B（01672）涨11.78%、再鼎医药（09688）涨6.55%
金吾财讯 · 10-06
创新药概念普升 歌礼制药-B（01672）涨11.78%、再鼎医药（09688）涨6.55%
异动解读｜中国生物制药盘中上涨3.15%，机构看好STADA合作前景
行情直击 · 10-06
异动解读｜中国生物制药盘中上涨3.15%，机构看好STADA合作前景
【券商聚焦】国金证券：行业有望迎业绩与估值戴维斯双击，创新药板块底部配置价值凸显
金吾财讯 · 10-05
【券商聚焦】国金证券：行业有望迎业绩与估值戴维斯双击，创新药板块底部配置价值凸显
中国生物制药发布9月股份变动月报表，股本维持不变
公告速递 · 10-02
中国生物制药发布9月股份变动月报表，股本维持不变
异动解读｜中国生物制药盘中下跌4.29%，报5.465港元
行情直击 · 10-02
异动解读｜中国生物制药盘中下跌4.29%，报5.465港元
中国生物制药盘中涨超4% 花旗维持“买入”评级
新浪港股 · 09-30
中国生物制药盘中涨超4% 花旗维持“买入”评级
异动解读｜中国生物制药盘中上涨3.33%，与STADA生物类似药合作持续催化
行情直击 · 09-30
异动解读｜中国生物制药盘中上涨3.33%，与STADA生物类似药合作持续催化
花旗：中国生物制药(01177)与STADA达成生物类似药战略合作 维持“买入”评级
智通财经 · 09-29
花旗：中国生物制药(01177)与STADA达成生物类似药战略合作 维持“买入”评级
中国生物制药就K药生物类似药达成海外授权，国产生物类似药出海再下一城
北京商报 · 09-29
中国生物制药就K药生物类似药达成海外授权，国产生物类似药出海再下一城
异动解读｜中国生物制药盘中上涨3.18%，与德国STADA达成生物类似药战略合作
行情直击 · 09-29
异动解读｜中国生物制药盘中上涨3.18%，与德国STADA达成生物类似药战略合作
中国生物制药：附属公司与STADA达成生物类似药合作，最高可获里程碑款5300万欧元
财中社 · 09-28
中国生物制药：附属公司与STADA达成生物类似药合作，最高可获里程碑款5300万欧元
中国生物制药（01177.HK）与德国 STADA 达成生物类似药合作，最高可获5,300万欧元里程碑款
公告速递 · 09-28
中国生物制药（01177.HK）与德国 STADA 达成生物类似药合作，最高可获5,300万欧元里程碑款
加载更多
公司概况
公司名称：
中国生物制药
所属市场：
SEHK
上市日期：
--
主营业务：
中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。
发行价格：
--
{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":5.41,"timestamp":1791533288000,"preClose":5.485,"halted":0,"volume":72670987,"delay":0,"changeRate":-0.01367365542388335,"floatShares":18683000000,"shares":18683000000,"eps":0.1522120018051533,"marketStatus":"休市中","change":-0.075,"latestTime":"10-09 16:08:08","open":5.55,"high":5.55,"low":5.355,"amount":392828720,"amplitude":0.035552,"askPrice":5.41,"askSize":127000,"bidPrice":5.405,"bidSize":632000,"shortable":3,"etf":0,"ttmEps":0.15568311888111885,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791768600000},"marketStatusCode":7,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":5.485,"dividendRate":0.0222,"openAndCloseTimeList":[[1791509400000,1791518400000],[1791522000000,1791532800000]],"volumeRatio":1.7452142166745812,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.2313,"impliedVolPercentile":0.122},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"2674892318","title":"【券商聚焦】中泰国际：多家药企将公布重要数据 推荐创新药与CXO龙头","url":"https://stock-news.laohu8.com/highlight/detail?id=2674892318","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674892318?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:38","pubTimestamp":1791506310,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际表示，多家创新药企业将于10月下旬ESMO公布重要临床数据。ESMO是欧洲最具盛名和影响力的肿瘤学会议，LBA是最高级别的研究成果展示，因此ESMO公布的LBA在医药行业广受关注。中国企业入选的LBA中，有四项入选最高级别的主席研讨会。该机构认为，以上情况表明中国创新药研发能力在海外广受认可，因此创新药板块值得继续关注。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993342","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WX","01177","09926","LU2097828557.USD","LU0348827113.USD","06160","LU1831875114.USD","LU2488822045.USD","MEDX","LU2399975544.HKD","LU0307460666.USD","LU0314109678.HKD","LU0708995153.HKD","LU1008478684.HKD","06978","159992","LU2125910500.SGD","IBBQ","LU1688375341.USD","02269","06821","LU0823426308.USD","BK1521","LU1960683339.HKD","LU2097828714.EUR","LU0149534421.HKD","LU0327786744.USD","LU0067412154.USD","LU0561508036.HKD","IE00BZ08YR35.GBP","KCE","BK1191","KURE","IE0008369823.USD","IE00B5MMRT66.SGD","LU0029874905.USD","02359","SG9999002463.SGD","00013","LU0320764599.SGD","02268","LU0572944931.SGD","LU0348767384.USD","01093","LU0348783233.USD","LNGR","LU1242518931.SGD","01801","CXO","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673079844","title":"新股消息 | 传圣因生物拟于明年赴港上市 已保密递交申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2673079844","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673079844?lang=zh_cn&edition=full","pubTime":"2026-10-08 18:50","pubTimestamp":1791456653,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据报道，圣因生物 采取保密递表方式向香港交易所递交上市申请，目标于明年IPO筹数亿美元，公司已聘请摩根士丹利及中金公司为联席保荐人。圣因生物成立于2021年，致力于开发针对自体免疫疾病、心血管疾病、肥胖及代谢性疾病的RNA干扰疗法 。圣因生物称，RNAi技术能够可逆性沉默致病基因。公司曾于2025年11月与礼来公司，完成RNAi药物研发策略合作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504771.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YT58.USD","BK1191","IE00BZ08YR35.GBP","01177","BK1521","IE00BZ08YS42.EUR","HK0000165453.HKD","BK1589","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673073463","title":"中国生物制药：附属公司TQC3721吸入混悬液III期临床完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2673073463","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673073463?lang=zh_cn&edition=full","pubTime":"2026-10-08 17:47","pubTimestamp":1791452820,"startTime":"0","endTime":"0","summary":"10月8日，中国生物制药（01177）发布公告，公司附属公司正大天晴自主研发的国家1类创新药TQC3721吸入混悬液“PDE3/4抑制剂”用于慢性阻塞性肺疾病(COPD)维持治疗的关键注册III期临床试验(PACER-III)，已于近期完成全部受试者入组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610083889733763.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610083889733763.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BZ08YR35.GBP","01177","HK0000165453.HKD","IE00BZ08YS42.EUR","BK1515","BK1589","BK1191","IE00BZ08YT58.USD","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673007895","title":"中国生物制药(01177.HK)：TQC3721吸入混悬液“PDE3/4抑制剂”III期注册临床完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2673007895","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673007895?lang=zh_cn&edition=full","pubTime":"2026-10-08 17:33","pubTimestamp":1791452016,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1589","IE00BZ08YS42.EUR","BK1191","IE00BZ08YR35.GBP","BK1521","BK1515","01177","HK0000165453.HKD","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142818659","title":"异动解读｜中国生物制药盘中下跌3.08%，跟随行业调整","url":"https://stock-news.laohu8.com/highlight/detail?id=1142818659","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142818659?lang=zh_cn&edition=full","pubTime":"2026-10-08 15:06","pubTimestamp":1791443215,"startTime":"0","endTime":"0","summary":"10月8日，中国生物制药盘中下跌3.08%，报5.5港元，成交额3.72亿港元。中国生物制药所在的制药行业中，整体呈现弱势，个股中，长风药业跌16.79%，石药集团跌5.20%，翰森制药跌4.54%，和黄医药跌3.13%，恒瑞医药跌1.26%。中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673041178","title":"港股开盘受压 恒指低开0.41% 汇丰控股（00005）跌2.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673041178","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673041178?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:27","pubTimestamp":1791422846,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股开盘受压，恒指低开0.41%，国企指数低开0.23%，恒生科技指数低开0.25%。汇丰控股跌2.40%，中国生物制药跌2.03%，华润电力跌1.97%，创科实业跌1.37%，万洲国际跌1.35%。剑桥科技低开2.01%，公司公告公布，拟配售1844.6万股。配售事项集资总额约为19.40亿港元，净额约19.30亿港元。初步转换价为每股H股128.82港元，较上交易日收市价114.30港元溢价约12.70%，可悉数转换为3598.33万股H股。乐动机器人低开1.52%，公司宣布，收购SABO-Maschinenfabrik GmbH全部股权，交易金额不超过600万欧元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/YWY0NWM4YTUxZGFlZmZjNmE5MDYxNjI4NjU1Mjc3NzM1Mzg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YWY0NWM4YTUxZGFlZmZjNmE5MDYxNjI4NjU1Mjc3NzM1Mzg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993270","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314109678.HKD","LU0048597586.USD","LU1152091754.HKD","LU1226287529.USD","LU0051755006.USD","LU0293314216.USD","LU0164865239.USD","LU0211977185.USD","LU0261947096.USD","BK1231","BK1142","BK1601","BK1619","LU1226287792.SGD","LU1226287875.USD","LU0029875118.USD","HK0000286598.CNH","IE00B031HY20.USD","LU0106259558.USD","LU1251922891.USD","TTNDY","LU0384037296.USD","LU1642822792.SGD","LU0417516902.SGD","LU0791590937.USD","89618","03032","LU0672654166.SGD","03033","HSBC","LU0456827905.SGD","LU1044875133.USD","SG9999001069.SGD","LU0431992006.USD","LU0173614495.USD","LU0163747925.USD","BK1179","LU0469268626.HKD","LU1119993845.HKD","LU0543330566.HKD","SG9999002950.SGD","LU0499858438.USD","SG9999001051.SGD","LU0650527681.SGD","HSBA.UK","LU1282649810.SGD","BK1543","BK1191","02228","LU0456842615.SGD","03143","IE0008368742.USD","LU0149534421.HKD","BK1589","LU0828237510.HKD","LU1226288170.HKD","KURE","LGFRY","00005","BK1175","LU0227179875.USD","LU0231483743.USD","LU0320764599.SGD","LU2929501877.USD","LU0877626530.USD","LU0259732245.USD","BK1513","BK1588","LU2039709279.SGD","LU2125910500.SGD","LU0501845795.SGD","IE0034224299.USD","BK1224","LU0228367735.SGD","LU0370786039.SGD","09088","LU0048580855.USD","IE0008369823.USD","LU0205439572.USD","LU1808992512.USD","IE00B543WZ88.USD","07226","09115","BK1125","LU0348805143.USD","LU1481107354.HKD","LU0072913022.USD","LU1719994722.HKD","IE00BGV7N243.SGD","LU0345776255.USD","LU0702159699.USD","LU2226246903.HKD","LU1105468828.SGD","513600","LU0307460666.USD","LU0326950275.SGD","BK1603","LU1282649067.USD","SG9999002828.SGD","IE0008368411.USD","BK1617","LU1366334651.USD","LU0516423091.SGD","LU0499858602.USD","82800","BK1577","LU1794554557.SGD","BK1183","SG9999001689.USD","JD","LU1770034418.SGD","03417","LU0588545904.SGD","IE00B3M56506.USD","LU1303224171.USD","BK1149","LU0128522157.USD","LU1224444064.USD","SG9999004220.SGD","LU2257852520.SGD","LU1366334578.USD","LU0084288322.USD","00178","HSHD.SI","03423","LU1720050803.USD","BK1249","BK1502","07200","BK1116","LU0348825331.USD","LU0588546209.SGD","LU0287142896.SGD","BK1555","LU0067412154.USD","03419","BK1592","LU0164880469.USD","LU0348735423.USD","LU0594300419.USD","LU0572944931.SGD","LU2045819591.USD","LU2177674079.SGD","LU0456846285.SGD","IE00BYTNYN87.SGD","LU0029874061.USD","LU0052750758.USD","LU1951186391.HKD","BK1237","LU1044874839.SGD","LU2187417386.USD","02837","LU0327786744.USD","LU0348816934.USD","LU0315179316.USD","LU0345775950.USD","01177","IE00B031J352.USD","LU0516423174.USD","LU0868486357.SGD","LU0541501648.USD","00288","LU1770036033.HKD","03750","IE00BZ08YS42.EUR","CRPJY","BK1615","LU0607220059.USD","IE0031814852.USD","LU1102505762.USD","BK1591","09618","BK1594","LU0039217434.USD","LU0348767384.USD","IE00B031HW06.USD","LU0348814723.USD","LU0540923850.HKD","BK1240","LU0543330483.HKD","LU1282651121.HKD","LU2449936058.SGD","BK1602","00960","00836","LU0274383008.USD","603083","BK1570","LU0488056044.USD","MCHmain","LU0791591158.USD","LU0048388663.USD","SBHMY","BK1525","LU0516422366.SGD","LU2351347302.SGD","IE0009570106.USD","LU0797268264.HKD","IE00B5MMRT66.SGD","LU0541502299.USD","07300","02600","LU0359201612.USD","LU1102505929.USD","03037","01093","601600","LU0315178854.USD","LU0128526141.USD","BK1521","IE00BYQNZ168.SGD","LU0320764755.SGD","LU0865486749.SGD","SG9999002562.SGD","09067","LU0359202008.SGD","BK1515","LU0918141705.HKD","IE00B0169N27.USD","LU0229945570.USD","SG9999000327.SGD","LU1008478684.HKD","300750","LU1960683339.HKD","LU0251144936.SGD","WHGLY","LU0588545490.SGD","07552","00669","01236","BK1575","02833","LU0588545730.USD","HSI","LU0708995583.HKD","LU1813983027.USD","LU0348766576.USD","LU0918141887.USD","LU1993786604.SGD","BK1141","03115","SG9999011746.SGD","BK1568","LU1044876610.USD","HK0000165453.HKD","LU0871576103.HKD","BK1610","SGXZ90724238.SGD","LU0140636845.USD","LU0149721374.USD","HHImain","BK1530","03088","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU1807302812.USD","LU1226288253.USD","07500","HSTECH","LU0880133367.SGD","LU1023057109.AUD","02800","LU0634319403.HKD","LU1282651048.USD","IE00B29SXG58.USD","LU1282648689.USD","LU2008162690.USD","LU0531971595.HKD","83115","LU1328277881.USD","LU2242644610.SGD","BK1572","SG9999001226.SGD","LU0359201885.HKD","IE0032431581.USD","LU1152091168.USD","06166","LU0228659784.USD","LU1166156734.SGD","IE00B12V2V27.USD","03067","LU0516422952.EUR","LU0516422440.USD","LU0417516738.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673062363","title":"【特约大V】邓声兴：外围暖恒指望企稳，科技超卖或先弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2673062363","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673062363?lang=zh_cn&edition=full","pubTime":"2026-10-07 10:16","pubTimestamp":1791339413,"startTime":"0","endTime":"0","summary":"外围暖恒指望企稳，科技超卖或先弹。合作亦包括最多三款额外肿瘤及免疫生物类似药期权。随着全球生物药专利悬崖来临，生物类似药市场需求庞大，集团凭藉自主开发及生产能力，有望持续拓展海外市场，成为新增长引擎。预期未来更多生物类似药品种将透过类似模式出海，带动授权收入及利润分成持续提升，中长线估值重估空间广阔。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/NmQyMzI4NWZmMGRlNDRmMTg4YmIyOTUwMDI3OTAzODMzODA5NjYxNDI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmQyMzI4NWZmMGRlNDRmMTg4YmIyOTUwMDI3OTAzODMzODA5NjYxNDI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993191","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCHmain","HK0000165453.HKD","07552","07300","03033","HHImain","513600","02800","07500","03417","03419","BK1191","HSI","BK1521","03423","83115","01177","07226","09115","BK1515","IE00BZ08YT58.USD","BK1589","IE00BZ08YR35.GBP","03067","03115","02833","03088","02837","09067","IE00BZ08YS42.EUR","07200","SBHMY","HSTECH","82800","03032","03037","09088"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673803803","title":"港股异动 | 创新药概念股涨势延续 美银指近期三项重磅合作强化板块动能 ESMO有望带来密集催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2673803803","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673803803?lang=zh_cn&edition=full","pubTime":"2026-10-06 10:05","pubTimestamp":1791252333,"startTime":"0","endTime":"0","summary":"美银证券发布研报称，中国医药/生物科技近期三项合作强化板块动能渤海证券表示，近期AI制药催化密集，行业焦点逐步从模型能力转向湿实验验证效率等方面，建议关注AI制药相关基因合成、蛋白表达、试剂耗材、动物模型及临床试验等细分赛道的投资机遇。同时，2026年ESMO年会即将召开，优异临床数据有望读出，带来板块密集催化，建议关注创新药、CXO及生命科学上游产业链等的投资机遇。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1503833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0561508036.HKD","HK0000165453.HKD","LNGR","BK1191","LU0348784397.USD","VXUS","09926","IE00B5MMRT66.SGD","LU0348766576.USD","LU0417516738.SGD","LU1794554557.SGD","LU0540923850.HKD","IE00BZ08YR35.GBP","LU0348735423.USD","LU0417516571.SGD","LU2399975544.HKD","LU2778985437.USD","06185","06978","01177","BK1574","KCAI","LU0348827113.USD","LU0417516902.SGD","LU2488822045.USD","LU0634319403.HKD","BK1521","IBBQ","BK1589","LU0348783233.USD","LU1720050803.USD","LU1961090484.USD","BK1515","159992","LU0348825331.USD","BK4588","LU2476274720.SGD","LU2476274308.USD","IE00BZ08YT58.USD","BK4585","BK1161","KURE","IE00BZ08YS42.EUR","MEDX","01672","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673734038","title":"创新药概念普升 歌礼制药-B（01672）涨11.78%、再鼎医药（09688）涨6.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673734038","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673734038?lang=zh_cn&edition=full","pubTime":"2026-10-06 09:54","pubTimestamp":1791251688,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念普涨，截至发稿，歌礼制药-B 涨11.78%，再鼎医药涨6.55%，金斯瑞生物科技涨5.30%，晶泰控股涨4.40%，中国生物制药涨3.96%，三生制药涨3.41%，药明生物涨3.16%，康方生物涨3.11%，云顶新耀涨3.10%，四环医药涨2.82%。2026ESMO已公布LBA标题，29项LBA的试验药物由中国药企原研或参与开发，涉及约20家企业，其中5项进入主席研讨会。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993103","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211977185.USD","KURE","IE00BPRC5H50.USD","LU2778985437.USD","01530","01952","00460","BK1141","LU1242518931.SGD","01672","LU0320764243.SGD","LU0348784397.USD","LU2476274308.USD","02228","06978","09688","LU0029874905.USD","LU0417516902.SGD","MEDX","HK0000306701.USD","LU0029874061.USD","BK4588","09926","01177","BK1521","ZLAB","01477","LNGR","LU0140636845.USD","IE00BZ08YT58.USD","LU0348827113.USD","LU0708995153.HKD","02269","LU0348766576.USD","159992","SG9999002463.SGD","LU0823426308.USD","01548","LU0320764599.SGD","LU0348735423.USD","LU0359201612.USD","IBBQ","BK1161","BK4139","BK1574","BK1191","LU0516422366.SGD","BK1515","LU0052750758.USD","LU0516423091.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156637968","title":"异动解读｜中国生物制药盘中上涨3.15%，机构看好STADA合作前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1156637968","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156637968?lang=zh_cn&edition=full","pubTime":"2026-10-06 09:43","pubTimestamp":1791250992,"startTime":"0","endTime":"0","summary":"10月6日，中国生物制药盘中上涨3.15%，延续近期上行走势。催化剂为花旗最新维持买入评级及目标价10.8港元，该判断基于旗下正大天晴与STADA达成的生物类似药战略合作。根据协议，公司可获得最高5300万欧元里程碑付款及双位数利润分成，2026年对外授权交易潜在总金额已累积至34亿美元。中国生物制药有限公司是一家主要从事制药业务的投资控股公司。其他分部主要从事相关医疗及医院业务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药上涨，STADA合作获机构看好","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673792787","title":"【券商聚焦】国金证券：行业有望迎业绩与估值戴维斯双击，创新药板块底部配置价值凸显","url":"https://stock-news.laohu8.com/highlight/detail?id=2673792787","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673792787?lang=zh_cn&edition=full","pubTime":"2026-10-05 08:50","pubTimestamp":1791161445,"startTime":"0","endTime":"0","summary":"随着后续管线商业化兑现、全球创新价值链话语权提升，行业有望迎来业绩与估值的戴维斯双击，创新药板块底部配置价值凸显。中国研究占全体大会核心LBA总量的1/3，这标志着中国肿瘤创新研发已深度融入全球研发体系，成为驱动全球肿瘤诊疗升级的重要力量，持续利好国内创新药企国际化发展与临床价值兑现。2026 ESMO已公布LBA标题，29项LBA的试验药物由中国药企原研或参与开发，涉及约20家企业，其中5项进入主席研讨会。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992996","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","LU1794554557.SGD","600109","01177","BK1161","LU0516422952.EUR","LU0043850808.USD","LU0315179316.USD","LU0540923850.HKD","LU2242644610.SGD","LU0359202008.SGD","LU1226287875.USD","159992","02269","BK1583","BK1610","LU0244354667.USD","LU0823426308.USD","LU2399975544.HKD","09688","01093","MEDX","LU0052750758.USD","LU0211977185.USD","01877","02616","LU1242518931.SGD","06978","LNGR","LU0856984785.SGD","02142","09926","HK0000165453.HKD","KURE","BK1515","06185","KCE","IBBQ","LU0314109678.HKD","LU0823426480.USD","09995","LU1807302812.USD","BK0201","BK1576","01801","IE0008368742.USD","LU1226288253.USD","06160","LU0455707207.USD","LU1328277881.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118259959","title":"中国生物制药发布9月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1118259959","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118259959?lang=zh_cn&edition=full","pubTime":"2026-10-02 10:16","pubTimestamp":1790907413,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司于2026年10月2日公布截至2026年9月30日的证券变动月报表。公告显示，公司本月法定/注册股本维持在300亿股，面值每股0.025港元，总额7.50亿港元。已发行股份合计仍为186.82952230亿股，本月无新增发股本，也无库藏股变动。根据公告显示，中国生物制药在2026年1月13日曾签订收购合同，计划向Dracoo Investment Limited以每股6.66港元发行约1459.6322万股普通股作为部分对价，但上述股份将在未来年度分期配发，目前本月并未实际发行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152057483","title":"异动解读｜中国生物制药盘中下跌4.29%，报5.465港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1152057483","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152057483?lang=zh_cn&edition=full","pubTime":"2026-10-02 09:42","pubTimestamp":1790905320,"startTime":"0","endTime":"0","summary":"10月2日，中国生物制药盘中下跌4.29%，报5.465港元，成交额3331.3万港元。中国生物制药所在的制药行业整体承压，个股中，翰森制药跌4.25%，石药集团跌3.77%，恒瑞医药跌3.59%，凯莱英跌5.99%，神威药业跌3.0%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671222653","title":"中国生物制药盘中涨超4% 花旗维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2671222653","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671222653?lang=zh_cn&edition=full","pubTime":"2026-09-30 11:30","pubTimestamp":1790739000,"startTime":"0","endTime":"0","summary":"模拟交易客户端中国生物制药盘中涨超4%，截至发稿，股价上涨2.79%，现报5.705港元，成交额2.15亿港元。该行认为合作带来惊喜，并维持中生制药“买入”评级，目标价10.8港元。根据协议，正大天晴将收取首付款及高达5，300万欧元的开发、监管及销售里程碑付款，并享有双位数利润分成；正大天晴仍负责开发、生产及商业供应，合作亦包括最多另外三个肿瘤及免疫领域生物类似药分子的选择权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-30/doc-initqqvm2508465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107465291","title":"异动解读｜中国生物制药盘中上涨3.33%，与STADA生物类似药合作持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1107465291","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107465291?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:27","pubTimestamp":1790735233,"startTime":"0","endTime":"0","summary":"9月30日，中国生物制药盘中上涨3.33%，报5.74港元，成交额9824.52万港元。消息面上，公司近日公告，附属公司正大天晴与德国药企STADA就帕博利珠单抗生物类似药TQB3570达成独家战略合作，授予STADA在欧盟、瑞士、英国及独联体的商业化权利，双方还可选择将最多三款肿瘤及免疫领域生物类似药纳入合作。公司透露年内对外授权交易累计首付款及近期里程碑付款已达3.55亿美元，潜在总交易金额达34亿美元，国际化布局持续加速。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药上涨，STADA合作持续催化","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671800297","title":"花旗：中国生物制药(01177)与STADA达成生物类似药战略合作 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2671800297","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671800297?lang=zh_cn&edition=full","pubTime":"2026-09-29 16:42","pubTimestamp":1790671365,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，中国生物制药旗下正大天晴与德国药企STADA就生物类似药达成战略合作，授予STADA在欧盟、瑞士、英国及独立国家联合体商业化帕博利珠单抗生物类似药的独家许可，并可选择拓展至美国及海湾合作委员会成员国市场。中生制药透露年内对外授权交易合计首付款及近期里程碑付款达3.55亿美元，潜在总交易金额达34亿美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1502057.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","PPH","XPH","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671529451","title":"中国生物制药就K药生物类似药达成海外授权，国产生物类似药出海再下一城","url":"https://stock-news.laohu8.com/highlight/detail?id=2671529451","media":"北京商报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671529451?lang=zh_cn&edition=full","pubTime":"2026-09-29 15:50","pubTimestamp":1790668212,"startTime":"0","endTime":"0","summary":"产品还未进入临床便火速敲定了合作。9月28日晚间，中国生物制药发布公告称，公司附属公司正大天晴药业集团股份有限公司与STADAArzneimittelAG已就生物类似药达成战略合作，授予后者在欧盟、瑞士、英国及独立国家联合体商业化帕博利珠单抗生物类似药TQB3570的独家许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609293886461514.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609293886461514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SBHMY","BK1589","IE00BZ08YR35.GBP","01177","BK1521","HK0000165453.HKD","BK1191","IE00BZ08YS42.EUR","BK1515","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181435389","title":"异动解读｜中国生物制药盘中上涨3.18%，与德国STADA达成生物类似药战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1181435389","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181435389?lang=zh_cn&edition=full","pubTime":"2026-09-29 09:47","pubTimestamp":1790646437,"startTime":"0","endTime":"0","summary":"9月29日，中国生物制药盘中上涨3.18%，报5.67港元，成交额5400.88万港元。消息面上，公司9月28日公告，附属公司正大天晴药业集团与德国STADA就帕博利珠单抗生物类似药TQB3570达成独家战略合作。STADA获得欧盟、瑞士、英国等地区的独家商业化权利，双方还可选择将最多三款肿瘤及免疫领域生物类似药纳入合作。公司年内已累计获得首付款及近期里程碑付款3.55亿美元，潜在总交易金额达34亿美元，国际化布局持续加速。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药放量上涨，与STADA达成战略合作","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670387092","title":"中国生物制药：附属公司与STADA达成生物类似药合作，最高可获里程碑款5300万欧元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670387092","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670387092?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:57","pubTimestamp":1790585820,"startTime":"0","endTime":"0","summary":"9月28日，中国生物制药（01177）发布公告，附属公司正大天晴药业集团股份有限公司与STADAArzneimittelAG已就生物类似药达成战略合作，双方将携手提升生物类似药在全球多个地区的患者可及性。根据协议的条款及条件，正大天晴将获得首付款，并有权获得潜在开发、监管及销售里程碑付款，合计最高可达5300万欧元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885246557.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885246557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2272731600.USD","PPH","BK1589","FXE","BK1515","BK4585","NBIE","BK4588","LU1992135472.HKD","IE00BZ08YR35.GBP","XPH","LU2473716301.USD","01177","IBB","LU2322448957.HKD","IE00BZ08YS42.EUR","BK1191","HK0000165453.HKD","LU1992135399.USD","IE00B5TLWC47.USD","LU2272731782.SGD","LU2272731865.HKD","IE00BZ08YT58.USD","LU2322448791.USD","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195589634","title":"中国生物制药（01177.HK）与德国 STADA 达成生物类似药合作，最高可获5,300万欧元里程碑款","url":"https://stock-news.laohu8.com/highlight/detail?id=1195589634","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195589634?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:53","pubTimestamp":1790585586,"startTime":"0","endTime":"0","summary":"2026年9月28日，中国生物制药公告称，其附属公司正大天晴药业集团股份有限公司与 STADA Arzneimittel AG 就帕博利珠单抗生物类似药达成战略合作，双方将共同提升该类产品在全球多地区的可及性。双方还约定，STADA可再选择最多三款覆盖肿瘤及免疫领域的生物类似药分子。公告显示，2026年以来，中国生物制药已完成多项对外授权交易，累计获得首付款及近期里程碑付款3.55亿美元，潜在总交易金额34亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":-0.0305},{"period":"1month","weight":-0.0357},{"period":"3month","weight":0.056},{"period":"6month","weight":-0.0637},{"period":"1year","weight":-0.2983},{"period":"ytd","weight":-0.1031}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":-0.0421},{"period":"3month","weight":0.0015},{"period":"6month","weight":-0.065},{"period":"1year","weight":-0.095},{"period":"ytd","weight":-0.0554}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.006945},{"month":2,"riseRate":0.652174,"avgChangeRate":0.056473},{"month":3,"riseRate":0.565217,"avgChangeRate":0.04606},{"month":4,"riseRate":0.478261,"avgChangeRate":0.020913},{"month":5,"riseRate":0.695652,"avgChangeRate":0.038341},{"month":6,"riseRate":0.347826,"avgChangeRate":0.004417},{"month":7,"riseRate":0.652174,"avgChangeRate":0.052281},{"month":8,"riseRate":0.434783,"avgChangeRate":-0.006702},{"month":9,"riseRate":0.434783,"avgChangeRate":-0.011268},{"month":10,"riseRate":0.521739,"avgChangeRate":0.021286},{"month":11,"riseRate":0.5,"avgChangeRate":0.067433},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.011901}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SBP GROUP"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}